Limula

Limula, founded in 2020 and based in Lausanne, Switzerland, is developing a novel manufacturing platform designed to automate and simplify cell and gene therapy production. Its core innovation is a single device that integrates a bioreactor with in-situ centrifugation, enabling complex, multi-step cell processing in a closed system to reduce contamination risk and hands-on time. The company targets the critical bottleneck of manufacturing capacity in the CGT field, aiming to catalyze broader patient access to these life-saving therapies. As a private, pre-revenue platform company, Limula is seeking strategic partnerships with biotechs, CDMOs, and pharma companies to advance its technology.

The LimOne platform is a closed, automated, all-in-one system for cell and gene therapy manufacturing. It uniquely integrates a bioreactor with in-situ centrifugation in a single device, enabling sequential cell processing steps (culture, media exchange, concentration) without manual intervention.

Limula competes in the CGT manufacturing automation space against large, diversified players like Thermo Fisher, Miltenyi, and Cytiva, as well as specialized startups. Its key differentiation is the physical integration of bioreactor and centrifuge functions into a single, closed, automated device, aiming to offer greater simplicity and lower hands-on time than modular, multi-vendor setups.